Company Overview and News
ZAMBOANGA CITY — Financially troubled Zamboanga City Electric Cooperative, Inc. (Zamcelco) is aiming to finally award an investment management contract (IMC) by Aug. 2 after two bidders submitted letters of intent.
ABZPF MER ABZPY AP
FIGHTING COAL Residents of Atimonan town, Quezon, and members of the group Power for People rally on Ortigas Avenue on June 5 to protest the continued construction of another coal power plant in Quezon province.—NIÑO JESUS ORBETA
ABZPF MER ABZPY AP
Malacañang ordered the chair of the Energy Regulatory Commission (ERC) to implement the suspension of four commissioners of the agency.
Electricity consumers in the capital region should expect an increase in their next monthly bill, as distribution utility Manila Electric Co. (Meralco) just announced an increase of P0.316 per kilowatt-hour (kWh).
Malacañang will carry out the suspension of four commissioners of the Energy Regulatory Commission (ERC) after they reportedly remained in their posts despite an order from the Office of the Ombudsman.
MANILA Electric Co. (Meralco) is looking at Isla Verde, an island in Batangas province within its franchise area, as a possible location for its first microgrid system, its president said.
Manila Electric Co. (Meralco) is looking at Isla Verde, an island within its franchise area, as its first venture in putting up a microgrid system, its president said.
Bayan Muna Rep. Carlos Isagani Zarate warned Energy Regulatory Commission (ERC) Chair Agnes Devanadera against inaction on seven power supply agreements (PSAs) pending at the agency but which militant legislators questioned for not going through public bidding.
Electricity sales in June has eased because of the cool weather, tempering power sales growth for the first half to around 6.5%, the top official of Manila Electric Co. (Meralco) said.
The benchmark Philippine Stock Exchange index (PSEi) continued its descent on Friday, briefly dropping below the 7,000 level before bargain hunters entered the fray.
MER SVTMF PSKXF MPCIY BDOUY AYAAY JBFCY SM BDOUF SMPH BDO SMIVY JBFCF MPI MPCFF SPHXY JFC PHSXY PSE SPHXF SPHZF ALI AYAAF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to PSE:MER / Manila Electric Company on message board site Silicon Investor.